Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19
Status:
Completed
Trial end date:
2021-07-09
Target enrollment:
Participant gender:
Summary
COVID-19 is associated with a cytokine storm that leads to respiratory distress, multiorgan
failure and elevated mortality. Oral Colchicine exhibits high anti-inflammatory capacity
attributed to the inhibition of microtubules polymerization, inflammasome and production of
IL-1β and IL-6, which could prevent the inflammatory storm in COVID-19 patients at risk. The
investigators present a randomized, controlled, open-labeled, and pragmatic clinical trial to
study the treatment effect of Colchicine in COVID-19 patients requiring hospitalization, but
no intensive care yet. Colchicine will be started within the first 48 hours and continue for
14 days using a descending dose. The benefits will be studied in terms of clinical evolution
(WHO 7-point scale) and IL-6 levels, as well as other clinical and biochemical secondary
end-points. In the case of positive results, the clinical impact would be relevant given that
this oral medication is affordable and widely accessible which would help to prevent the
inflammatory complications associated with COVID-19.